Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215
Conditions
Interventions
ASP2215
Locations
1
United States
Site US10001
Miami, Florida, United States
Start Date
October 23, 2015
Primary Completion Date
March 5, 2016
Completion Date
March 5, 2016
Last Updated
November 5, 2024
NCT07310264
NCT06290258
NCT06716502
NCT00090662
NCT07483606
NCT07310901
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions